The following sentence was inadvertently duplicated on page 835: Subsequently, several other nanomedicinal therapeutics have been approved for clinical use, including an albumin-bound nanoparticle delivering paclitaxel for the treatment of breast cancer (Abraxane; Abraxis BioScience) and liposomal amphotericin B for the treatment of fungal infections (AmBisome; Astellas Pharma). This has been removed from the online version.
Additional information
The online version of the original article can be found at 10.1038/nrd3578
Rights and permissions
About this article
Cite this article
Lobatto, M., Fuster, V., Fayad, Z. et al. Erratum: Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 10, 963 (2011). https://doi.org/10.1038/nrd3614
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3614
This article is cited by
-
Magnetic nanoparticle drug targeting to patient-specific atherosclerosis: effects of magnetic field intensity and configuration
Applied Mathematics and Mechanics (2020)
